Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review
Pharmaceuticals · 21.11.2024 · 17 (12) · 1563
DOI: 10.3390/ph17121563 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.11.2024. Verfasst von Ming-Cheng Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Isotope Research Application, National Atomic Research Institute, Taoyuan 325207, Taiwan. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, National Science and Technology Council of Taiwan.
Abstract (Originalsprache)
Iodine-123 metaiodobenzylguanidine (I-123 MIBG) is a crucial radiopharmaceutical widely used in nuclear medicine for its diagnostic capabilities in both cardiology and oncology. This review aims to present a comprehensive evaluation of the clinical applications of I-123 MIBG, focusing on its use in diagnosing and managing various diseases. In cardiology, I-123 MIBG has proven invaluable in assessing cardiac sympathetic innervation, particularly in patients with heart failure, where it provides prognostic information that guides treatment strategies. In oncology, I-123 MIBG is primarily utilized for imaging neuroendocrine tumors, such as neuroblastoma and pheochromocytoma, where it offers high specificity and sensitivity in the detection of adrenergic tissue. Additionally, its role in neurology, specifically in differentiating between Parkinson’s disease, dementia, and Lewy body dementia, has become increasingly significant due to its ability to identify postganglionic sympathetic dysfunction. Despite its established clinical utility, the use of I-123 MIBG is not without limitations, including variability in imaging protocols and interpretation challenges. This review will explore these issues and discuss emerging alternatives, while also highlighting areas where I-123 MIBG continues to be a gold standard. By synthesizing the current research, this article aims to provide a clear understanding of the strengths, limitations, and prospects of I-123 MIBG in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Isotope Research Application, National Atomic Research Institute, Taoyuan 325207, Taiwan.
- Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.
- Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei 100226, Taiwan.
- Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu 302058, Taiwan.
ORCID-Profile: Ming-Cheng Chang, Yi-Jou Tai, Ying-Cheng Chiang
Förderung
- National Science and Technology Council
- National Science and Technology Council of Taiwan
Zitieren
APA
Chang, M. C., Peng, C. L., Chen, C. T., Shih, Y. H., Chen, J. H., Tai, Y. J., & Chiang, Y. C. (2024). Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals, 17(12), 1563. https://doi.org/10.3390/ph17121563
Vancouver
Chang MC, Peng CL, Chen CT, Shih YH, Chen JH, Tai YJ, et al. Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals. 2024;17(12):1563. doi:10.3390/ph17121563
BibTeX
@article{Chang2024,
author = {Chang, Ming-Cheng and Peng, Cheng-Liang and Chen, Chun-Tang and Shih, Ying-Hsia and Chen, Jyun-Hong and Tai, Yi-Jou and Chiang, Ying-Cheng},
title = {Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {12},
pages = {1563},
doi = {10.3390/ph17121563}
}
EUVIMED